Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADAPTOS

Financiado

Cerrado

ADAPTOS Changing the way bone voids are treated

There are 4 million operations performed annually that require a bone graft. This makes bone the second most common tissue transplant in the world, trailing only blood transfusions. There are three options where to source the bo... ver más

30/09/2024

Biomendex Oy

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

BIOMENDEX OY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-09-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Biomendex Oy

2.25M€ | Lider

AISOY ROBOTICS

174.73K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

REGENERBONE REGENERATING LARGE BONE DEFECTS 150K€ Cerrado

REBOOT First in class implants for bone regeneration surgery after... 4M€ Cerrado

CHARME Growing bone fast and cost effective 3M€ Cerrado

REBORNE Regenerating Bone defects using New biomedical Engineering a... 15M€ Cerrado

BioBone BioBone: Bioactive Hydrogel-based Implants to Induce Bone Re... Cerrado

REGENKNEE Re engineering and regenerating the knee 2M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2019-09-24
Fecha Fin: 2024-09-30

Líder del proyecto

BIOMENDEX OY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto There are 4 million operations performed annually that require a bone graft. This makes bone the second most common tissue transplant in the world, trailing only blood transfusions. There are three options where to source the bone today. Directly from the patient (autograft), from a bone bank (allograft) or using a substitute. The dominant method today is autografting. This is because human’s own bone is easy to use and offers plentiful regeneration properties. However, autografting is painful and risky, causing complications in 50% of harvests. This has caused orthopaedic surgeons to regard autografting as a trade-off between sourcing a suitable bone at the cost of a minor disability for the patient. This is where Adaptos comes in. Adaptos is the only bone graft substitute that mimics bone by being resilient and bioactive. Adaptos gives surgeons the freedom to operate, as they were using autografts, without the drawbacks. Today, Adaptos is already in use across 9 animal clinics. By collaborating with numerous surgeons, we have validated our technology as the best bone graft substitute on the market. We will initially enter the synthetic bone graft substitute market valued at €2.1 billion. We aim to penetrate the less complex markets first (animals, craniomaxillofacial & orthopaedic applications). Through these applications, we will build reference cases to meet the high burden-of-proof required to enter the most complex applications (e.g. Spinal fusion). Our cross-disciplinary founding team will use the SME-project to scale up Adaptos’ production line, build reference cases across 3 hospitals via a multi-country clinical trial and improve our onboarding of orthopaedic surgeons in the process. Thanks to the SME-project, we estimate that we will reach €17 million in revenue by 2023 while employing 35 high-quality employees.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores